American Heart Association (AHA)

The American Heart Association (AHA) funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke. The AHA also is a key resource for the latest cardiology science through its journals and annual meeting.

Most adults know nothing about CKM syndrome—but it impacts nearly everyone
Nearly 90% of adults are believed to already have at least one risk factor of CKM syndrome. The American Heart Association hopes patient education and physician collaborations can help increase awareness about this dangerous condition.
Hospital in Mexico earns first heart failure certification of its kind
A facility outside the United States has received the American Heart Association's Comprehensive Heart Failure Center Certification for the first time.
Advances in imaging could help predict, prevent heart attacks
Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away.
Long-term data highlight Ross procedure's safety, effectiveness in younger patients
TAVR may get more attention, but the Ross procedure has also gained significant momentum in recent years. Ismail El-Hamamsy, MD, PhD, detailed his own team's success with the complex procedure.
Common methods for attributing cardiac care in ACOs may be falling short
As the United States continues to move toward quality-based care, ACOs need to rethink the way they attribute care to cardiologists and other members of the heart team.

Poor mental health leads to higher CVD risk in young adults

Even among people who do not experience any major cardiovascular events, researchers noted, there are strong associations between poor mental health and poor heart health.

Infertility linked to a higher risk of coronary heart disease

The associations were strongest for women who experienced infertility at the age of 25 or younger.

PCI with a DES: Comparing 10-year outcomes between men and women

One key takeaway was that women faced a higher MI risk than men, but only for the first 30 days.

Sahil Parikh explains the tread of cardiology departments treating critical limb ischemia (CLI) at AHA 2022.

Interventional cardiology's role in treating CLI continues to evolve

Sahil Parikh, MD, talked to Cardiovascular Business about growing trends related to the treatment of critical lower limb ischemia. "We are getting better and better at saving their limbs, but we are not better at saving their lives," he said.

Incoming 2023-2024 American College of Cardiology (ACC) president Hadley Wilson, MD, shares insights on how to create health equity through both ACC programs and hospital grassroots community outreach programs. He outlines four programs his heart hospital is piloting in its community in Charlotte, North Carolina.

How cardiologists can address health disparities in their communities

Incoming 2023-2024 American College of Cardiology president Hadley Wilson, MD, shared insights on how to create health equity through grassroots community outreach programs.

Sahil A. Parikh, MD, Director of Endovascular Services at Columbia University Irving Medical Center and Associate Professor of Medicine at the Columbia University College of Physicians and Surgeons, explained the growing trend or interventional cardiologists treating PAD and CLI. He shares what he thinks is important for cardiology departments to know before expanding expanding their programs in this space.

What do interventional cardiologists need to treat PAD and CLI?

Sahil Parikh, MD, director of endovascular services at Columbia University Irving Medical Center, said treating these patients can be quite challenging.

New ACC/AHA/SCAI guidance highlights training requirements for interventional cardiologists

The document, which was designed to help guide both interventional cardiology trainees and program directors, was also endorsed by several other industry societies.

Bertram Pitt, MD, a professor of medicine emeritus at the University of Michigan School of Medicine, explains the role of sodium–glucose co-transporter-2 (SGLT-2) inhibitors for heart failure (HF). Initially developed to treat diabetes, these drugs have been shown to improve HF outcomes in HF in several large, randomized trials over the past few years, including SOLOIST-WHF, DAPA-HF, EMPEROR-Preserved, and the DELIVER trials. The positive results earned their inclusion in the 2022 AHA/ACC/HFSA Guideline for

What clinical research tells us about sotagliflozin and heart failure

Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.

American Heart Association (AHA)

Most adults know nothing about CKM syndrome—but it impacts nearly everyone

Hospital in Mexico earns first heart failure certification of its kind

Advances in imaging could help predict, prevent heart attacks

Long-term data highlight Ross procedure's safety, effectiveness in younger patients

Common methods for attributing cardiac care in ACOs may be falling short